Results 231 to 240 of about 80,496 (333)

Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6691-6704, November 2025.
Abstract Aims In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real‐world settings.
Kim G. Smolderen   +10 more
wiley   +1 more source

Diagnostic yield of whole exome sequencing with targeted gene analysis in prelingual sensorineural hearing loss in Thailand. [PDF]

open access: yesSci Rep
Damrongchietanon T   +8 more
europepmc   +1 more source

IFN for Treatment of Severe Idiopathic Sudden Sensorineural Hearing Loss. IFN Therapy without Steroids.

open access: bronze, 1995
Shinnichi Kanemaru   +4 more
openalex   +2 more sources

Different Distribution of HLA Class II Alleles According to Response to Corticosteroid Therapy in Sudden Sensorineural Hearing Loss [PDF]

open access: bronze, 2001
Sang Won Yeo   +6 more
openalex   +1 more source

Deferoxamine Mesylate-Associated Sensorineural Hearing Loss

open access: bronze, 1995
Hidetaka Kanno   +3 more
openalex   +2 more sources

Improvement of Speech Recognition with Zero-Crossing in Patients with Sensorineural Hearing Loss.

open access: bronze, 1995
Kôji Miyata   +5 more
openalex   +2 more sources

Sensorineural hearing loss and retinopathy in sickle cell patients. [PDF]

open access: yesJ Surg Case Rep
Ewusi-Wilson RK   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy